| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C J Bachmann, D Lehr, F M Theisen, M Preis. Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry. vol 42. issue 4. 2009-09-15. PMID:19585394. |
aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. |
2009-09-15 |
2023-08-12 |
Not clear |
| Tracy S Cummings, Douglas L Noords. Treatment of catatonic schizophrenia with lorazepam and aripiprazole. Schizophrenia research. vol 112. issue 1-3. 2009-09-03. PMID:19411162. |
treatment of catatonic schizophrenia with lorazepam and aripiprazole. |
2009-09-03 |
2023-08-12 |
Not clear |
| David C Henderson, Xiaoduo Fan, Paul M Copeland, Bikash Sharma, Christina P Borba, Ryan Boxill, Oliver Freudenreich, Corinne Cather, A Eden Evins, Donald C Gof. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of clinical psychopharmacology. vol 29. issue 2. 2009-08-18. PMID:19512978. |
aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. |
2009-08-18 |
2023-08-12 |
human |
| David C Henderson, Xiaoduo Fan, Paul M Copeland, Bikash Sharma, Christina P Borba, Ryan Boxill, Oliver Freudenreich, Corinne Cather, A Eden Evins, Donald C Gof. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of clinical psychopharmacology. vol 29. issue 2. 2009-08-18. PMID:19512978. |
we report the results of a 10-week placebo-controlled, double-blind crossover study that examined 15 mg/d aripiprazole's effects on weight, lipids, glucose metabolism, and psychopathology in overweight and obese schizophrenia and schizoaffective disorder subjects treated with a stable dose of olanzapine. |
2009-08-18 |
2023-08-12 |
human |
| Hitoshi Takahashi, Takashi Oshimo, Jun Ishigook. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. Clinical neuropharmacology. vol 32. issue 3. 2009-08-10. PMID:19483480. |
efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. |
2009-08-10 |
2023-08-12 |
Not clear |
| Hitoshi Takahashi, Takashi Oshimo, Jun Ishigook. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. Clinical neuropharmacology. vol 32. issue 3. 2009-08-10. PMID:19483480. |
the purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. |
2009-08-10 |
2023-08-12 |
Not clear |
| F Bergmann, A Zacher, A Nass, R Urban, C Werner, T Spevakné-Göröcs, M Kungel, M Ebrecht, S Model. Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study. Pharmacopsychiatry. vol 42. issue 3. 2009-08-06. PMID:19452378. |
psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. |
2009-08-06 |
2023-08-12 |
Not clear |
| V Ryckmans, J P Kahn, S Modell, C Werner, R D McQuade, W Kerselaers, J Lissens, R Sanche. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. vol 42. issue 3. 2009-08-06. PMID:19452380. |
switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. |
2009-08-06 |
2023-08-12 |
Not clear |
| V Ryckmans, J P Kahn, S Modell, C Werner, R D McQuade, W Kerselaers, J Lissens, R Sanche. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. vol 42. issue 3. 2009-08-06. PMID:19452380. |
this study evaluated the safety/tolerability and effectiveness of aripiprazole titrated-dose versus fixed-dose switching strategies from risperidone in patients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues. |
2009-08-06 |
2023-08-12 |
Not clear |
| Taku Nagai, Rina Murai, Kanae Matsui, Hiroyuki Kamei, Yukihiro Noda, Hiroshi Furukawa, Toshitaka Nabeshim. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology. vol 202. issue 1-3. 2009-08-05. PMID:18679658. |
aripiprazole, an atypical antipsychotic drug, has been shown to improve disruption of prepulse inhibition and social interaction in an animal model of schizophrenia induced by phencyclidine (pcp); however, the effects of aripiprazole on recognition memory remain to be investigated. |
2009-08-05 |
2023-08-12 |
Not clear |
| Wen-Yu Hsu, Chien-I Lee, Nan-Ying Chiu, David A Kah. Aripiprazole in treatment-refractory schizophrenia. Journal of psychiatric practice. vol 15. issue 3. 2009-08-04. PMID:19461396. |
aripiprazole in treatment-refractory schizophrenia. |
2009-08-04 |
2023-08-12 |
Not clear |
| Wen-Yu Hsu, Chien-I Lee, Nan-Ying Chiu, David A Kah. Aripiprazole in treatment-refractory schizophrenia. Journal of psychiatric practice. vol 15. issue 3. 2009-08-04. PMID:19461396. |
this report describes the case of a 58-year-old female patient with treatment-refractory schizophrenia who was successfully switched from clozapine 300 mg/day to aripiprazole 20 mg/day because of changes in consciousness. |
2009-08-04 |
2023-08-12 |
Not clear |
| Robert G Stern, Theodore A Petti, Kurt Bopp, Anthony Tobi. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. Journal of clinical psychopharmacology. vol 29. issue 3. 2009-08-03. PMID:19440071. |
aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. |
2009-08-03 |
2023-08-12 |
Not clear |
| Robert G Stern, Theodore A Petti, Kurt Bopp, Anthony Tobi. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. Journal of clinical psychopharmacology. vol 29. issue 3. 2009-08-03. PMID:19440071. |
this open-label study tested the hypothesis that a switchover to aripiprazole would reduce the severity of social anxiety in patients, who have schizophrenia with co-occurring social anxiety, treated with neuroleptic medications. |
2009-08-03 |
2023-08-12 |
Not clear |
| Polash Shajahan, Sonia Keith, Chetan Majjiga, Jennifer Murphy, Alison MacRae, Muhammad Bashir, Mark Taylo. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study. The Journal of clinical psychiatry. vol 70. issue 5. 2009-07-22. PMID:19284930. |
comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study. |
2009-07-22 |
2023-08-12 |
Not clear |
| Anthony H Barnett, Helen L Millar, Jean-Yves Loze, Gilbert J L'Italien, Marc van Baardewijk, Martin Knap. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). European archives of psychiatry and clinical neuroscience. vol 259. issue 4. 2009-07-15. PMID:19267255. |
uk cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (star study). |
2009-07-15 |
2023-08-12 |
Not clear |
| Anthony H Barnett, Helen L Millar, Jean-Yves Loze, Gilbert J L'Italien, Marc van Baardewijk, Martin Knap. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). European archives of psychiatry and clinical neuroscience. vol 259. issue 4. 2009-07-15. PMID:19267255. |
assuming the risk of diabetes onset/chd events remained linear over 10 years, these risks were used to estimate the difference in direct and indirect cost consequences of diabetes and chd in schizophrenia patients treated with aripiprazole or soc over a 10-year period. |
2009-07-15 |
2023-08-12 |
Not clear |
| Anthony H Barnett, Helen L Millar, Jean-Yves Loze, Gilbert J L'Italien, Marc van Baardewijk, Martin Knap. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). European archives of psychiatry and clinical neuroscience. vol 259. issue 4. 2009-07-15. PMID:19267255. |
compared with soc, aripiprazole treatment may provide reductions in the health and economic burden to schizophrenia patients and health care services in the uk as a result of its favourable metabolic profile. |
2009-07-15 |
2023-08-12 |
Not clear |
| Michela Nosè, Simone Accordini, Paola Artioli, Francesco Barale, Corrado Barbui, Rossella Beneduce, Domenico Berardi, Gerardo Bertolazzi, Bruno Biancosino, Alfredo Bisogno, Raffaella Bivi, Filippo Bogetto, Marianna Boso, Alberto Bozzani, Piera Bucolo, Marcello Casale, Liliana Cascone, Luisa Ciammella, Alessia Cicolini, Gabriele Cipresso, Andrea Cipriani, Paola Colombo, Barbara Dal Santo, Michele De Francesco, Giorgio Di Lorenzo, Walter Di Munzio, Giuseppe Ducci, Arcadio Erlicher, Eleonora Esposito, Luigi Ferrannini, Farida Ferrato, Antonio Ferro, Nicoletta Fragomeno, Vincenzo Fricchione Parise, Maria Frova, Francesco Gardellin, Nicola Garzotto, Andrea Giambartolomei, Giancarlo Giupponi, Luigi Grassi, Natalia Grazian, Lorella Grecu, Gualtiero Guerrini, Francesco Laddomada, Ermanna Lazzarin, Camilla Lintas, Francesca Malchiodi, Lara Malvini, Livio Marchiaro, Alessandra Marsilio, Massimo Carlo Mauri, Antonio Mautone, Marco Menchetti, Giuseppe Migliorini, Marco Mollica, Daniele Moretti, Serena Mulè, Stylianos Nicholau, Flavio Nosè, Guglielmo Occhionero, Anna Maria Pacilli, Stefania Pecchioli, Mauro Percudani, Ennio Piantato, Carlo Piazza, Francesco Pontarollo, Roger Pycha, Roberto Quartesan, Luciana Rillosi, Francesco Risso, Raffella Rizzo, Paola Rocca, Stefania Roma, Matteo Rossattini, Giuseppe Rossi, Giovanni Rossi, Alessandra Sala, Claudio Santilli, Giuseppe Saraò, Antonio Sarnicola, Francesca Sartore, Silvio Scarone, Tiziana Sciarma, Alberto Siracusano, Stefania Strizzolo, Michele Tansella, Gino Targa, Annamarie Tasser, Rodolfo Tomasi, Rossana Travaglini, Antonio Veronese, Simona Zier. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials. vol 10. 2009-07-09. PMID:19445659. |
rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. |
2009-07-09 |
2023-08-12 |
Not clear |
| John M Kane, Olawale Osuntokun, Ludmila A Kryzhanovskaya, Wen Xu, Virginia L Stauffer, Susan B Watson, Alan Breie. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. The Journal of clinical psychiatry. vol 70. issue 4. 2009-06-30. PMID:19323965. |
a 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. |
2009-06-30 |
2023-08-12 |
Not clear |